SCHEMBL21472528

SCHEMBL21472528

CCCCNc1c(N(CC)CC)c(=O)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
MAPT P10636 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.36
TDP1 Q9NUW8 1/20 0.36
KDM4E B2RXH2 4/20 0.36
GAA P10253 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MCL1 Q07820 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HTT P42858 1/20 0.35
ADAMTS5 Q9UNA0 1/20 0.34
CYP1A2 P05177 1/20 0.33
ITGB1 P05556 1/20 0.33
ITGA4 P13612 1/20 0.33
APAF1 O14727 1/20 0.33
USP2 O75604 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
GRIN2D O15399 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21231008 0.95 MAPT (0.37) ALDH1A1MAPTL3MBTL1MCL1ADAMTS5
SCHEMBL21842751 0.89 MCL1 (0.34) ALDH1A1MAPTL3MBTL1KDM4EGAA
SCHEMBL21473510 0.84 ALDH1A1 (0.35) ALDH1A1MAPTL3MBTL1TDP1KDM4E
SCHEMBL22645965 0.84 ALDH1A1 (0.35) ALDH1A1MAPTL3MBTL1TDP1KDM4E
SCHEMBL21842762 0.84 ALDH1A1 (0.40) ALDH1A1MAPTL3MBTL1TDP1KDM4E
SCHEMBL18665157 0.83 ALDH1A1 (0.41) ALDH1A1MAPTL3MBTL1TDP1KDM4E
SCHEMBL21842636 0.83 TSHR (0.35) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL21473460 0.83 ITGB1 (0.31) ITGB1ITGA4USP2HPGDTSHR
SCHEMBL21842759 0.82 ALDH1A1 (0.31) ALDH1A1ITGB1ITGA4
SCHEMBL21842779 0.82 ALDH1A1 (0.39) ALDH1A1MAPTL3MBTL1TDP1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021155267-A2 MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF MODERNATX, INC. (US) 2021-08-05 WO disclosed
WO-2021076805-A1 MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF Moderna TX, Inc. (US) 2021-04-22 WO disclosed
WO-2020227537-A1 DIFFERENTIALLY EXPRESSED IMMUNE CELL MICRORNAS FOR REGULATION OF PROTEIN EXPRESSION Modernatx, Inc (US) 2020-11-12 WO disclosed
WO-2020061367-A1 COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS MODERNATX, INC. (US) 2020-03-26 WO disclosed
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS MODERNATX, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190314291-A1 COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS LCP2, CD14, MYD88 ALDH1A1 4722/4885MAPT 2204/4885L3MBTL1 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.